A comparison of intranasal and oral flunisolide in the therapy of allergic rhinitis. Evidence for a topical effect.

摘要: Intranasal flunisolide is an effective treatment for allergic rhinitis. Flunisolide has high bioavailability when administered to normal subjects (50% of intranasal dose reaches the systemic circulation) with minimal effects. Bioavailability in patients active rhinitis averages 62.4 +/- 15.7%. The oral bioequivalent 100 micrograms intranasally 500 micrograms. To define comparative trial and effects rhinitis, a multicenter, randomized, double-blind, placebo-controlled study was conducted during 1983 ragweed hayfever season. Ninety-nine greater than or equal 2 years positive prick skin tests were randomly allocated one three groups: 0 = b.i.d. placebo b.i.d.; N 50 per nostril P Treatment continued 4 weeks. Patients kept daily symptom scores. evaluated by blinded observer every weeks globally at study's end. Data analyzed each center pooled. There no significant differences severity sneezing, nasal congestion, throat itch (oral flunisolide) (placebo) groups. (nasal significantly more O (P less 0.005) least 2-week period. Global evaluation demonstrated control overall but not flunisolide). We conclude that therapeutic efficacy achieved topical action.